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Cartilage generation and degradation are regulated by miRNAs. Our previous study has shown
altered expression of miR-193b in chondrogenic human adipose-derived mesenchymal stem cells
(hADSCs). In the current study, we investigated the role of miR-193b in chondrogenesis and cartilage
degradation. Luciferase reporter assays showed that miR-193b targeted seed sequences of the TGFB2
and TGFBR3 30-UTRs. MiR-193b suppressed the expression of early chondrogenic markers in chon-
drogenic ATDC5 cells, and TNF-alpha expression in IL-1b-induced PMCs. In conclusion, MiR-193b
may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inﬂammation
by repressing TNF-alpha expression in inﬂamed chondrocytes.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Cartilage tissues are degraded and destroyed during the process
of osteoarthritis and cartilage is unable to recover on its own.
Thus, cure or prevention of osteoarthritis requires an understand-
ing of the molecular mechanisms of cartilage generation and
degradation.
Multiple factors and signaling pathways regulating cartilage
generation and degradation have been identiﬁed [1,2]. Chondro-
genesis is usually divided into two stages: early chondrogenesis,
characterized by upregulated collagen 2 (col2a1) and sox9, and
hypertrophy, characterized by upregulated collagen 10 (col10a1)
and runx2. These two stages are regulated by multiple factors
and signaling pathways [3], and they function to repress each other
[4–7]. Among these signaling pathways, the TGF-beta pathwayfunctions to enhance early chondrogenesis, repressing hypertro-
phy and degradation of cartilage [8–10]. Many stimuli activates
TGF-beta signaling [11,12] and activate smad2 and smad3 phos-
phorylation [10]. Phosphorylated smad3 induces chondrogenesis
through activation of sox9 [13], which is the pivotal factor in early
chondrogenesis [14]. TGF-beta receptor 3 (TGFBR3) is another
enhancer of the TGF-beta pathway. Although it does not directly
activate downstream phosphorylation of smads after ligand
binding, it functions to present ligands to TGF-beta receptors 1
and 2, and increase the afﬁnity of TGF-beta receptors 1 and 2 to
the ligand [15].
The microRNAs (miRNAs, miRs) are a class of small, non-coding,
single-stranded RNAs identiﬁed as important post-transcriptional
regulators. The miRNAs either repress the translation of mRNA of
target genes or induce mRNA degradation, usually by the
complementary base pairing of mature miRNAs and the 30-UTR
(untranslated region) of the target gene’s mRNA. MiRNAs have
been reported to have important roles in multiple biological pro-
cesses, including differentiation, development, proliferation, and
tumorigenesis.
Several miRNAs was conﬁrmed to participate in the processes of
cartilage differentiation and degradation [16–18], and these miR-
NAs were identiﬁed as either enhancing or inhibiting chondro-
genesis. MiR-365 has been shown to enhance chondrogenesis by
targeting HDAC4 [19], and miR-145 has been shown to inhibit ear-
ly chondrogenesis by targeting sox9 [20]. Other miRNAs regulate
chondrogenesis by targeting components of the TGF-beta signaling
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geting TGF-beta receptor 2 [21], and miR-455 regulates chondro-
genesis by targeting ACVR2B, SMAD2, and CHRDL1, all of which
belong to the TGF-beta pathway [22]. However, the roles of addi-
tional miRNAs in chondrogenesis require clariﬁcation.
Previously, we found that miR-193b expression changed sig-
niﬁcantly during chondrogenesis of human mesenchymal stem
cells. We also predicted the possible target genes of miR-193b
using prediction softwares and the literatures [23]. Based on our
previous work, we hypothesized that miR-193b may contribute
to chondrogenesis and osteoarthritis. In this work, we continue
to investigate the speciﬁc biological functions and mechanisms of
miR-193b.
2. Materials and methods
2.1. hADSCs culture and chondrogenesis
The hADSCs (human adipose-derived mesenchymal stem cells)
were cultured for expansion, as described in Supplementary
materials.
The hADSCs were harvested and resuspended in incomplete
mesenchymal stem cell chondrogenic differentiation medium
(Cyagen, HUXMA-03041-194, China) at 2  107 cells/ml. Droplets
(12.5 ll) were carefully placed in each well of a 24-well plate. Cells
were allowed to adhere at 37 C for 90 min, followed by the addi-
tion of 500 ll chondrogenic differentiation medium [23–26]. The
chondrogenic medium was replaced every 3 days.
2.2. ATDC5 cell culture and chondrogenesis
ATDC5 cells were cultured and induced to chondrogenesis as
described in Supplementary materials.
2.3. Primary chondrocyte isolation and culture
Mice were maintained in accordance with the guidelines of the
Animal Center of First Afﬁliated Hospital of Sun Yat-Sen University.
Isolation of primary mouse chondrocytes (PMCs) was performed as
previously described [27]. The method of mice chondrocyte isola-
tion was in Supplementary materials.
Primary mouse chondrocytes were cultured to allow expansion
in M199 (Gibco, 11150-059, USA) plus 10% FBS, 1% penicillin and
streptomycin, bFGF (Peprotech, 450-33, USA), EGF (Peprotech,
315-09, USA), insulin (Sigma, 11070-73-8, USA), in a 37 C and
5% CO2 humid atmosphere.
The procedures followed were in accordance with the ethical
standards of the ethical committee on human experimentation
(First Afﬁliated Hospital of Sun Yat-Sen University, China) and with
the Helsinki Declaration of 1975, as revised in 2000. After informed
consent, primary human chondrocytes (PHCs) were isolated from
the cartilage of patients suffering a fracture of the hip or knee joint
during operation. Patients with degraded cartilages, local or sys-
temic immunological disorders, or tumors were excluded. The
method of isolation was described in Supplementary materials.
Primary human chondrocytes were cultured in DMEM/F12 plus
5% FBS and 1% penicillin and streptomycin, in a 37 C and 5% CO2
humid atmosphere.
2.4. Interleukin-1beta-induced chondrocytes
Before stimulation with interleukin-1beta (IL-1b), ATDC5 cells
were incubated in chondrogenic medium with ITS+ Premix for
14 days. Chondrogenic ATDC5 cells, PHCs and PMCs (after no more
than 4 passages) were treated with the indicated doses ofrecombinant IL-1b (Peprotech, 200-01B, USA) for the indicated
times [28–30].
2.5. Staining and microscopy
The micromass was harvested at the indicated time points. The
macro-morphology was examined by photography (Leica, M205FA,
Switzerland). The pathology was examined using formalin ﬁxation,
parafﬁn embedding method, and alcian blue staining [26].
Cultured ATDC5 cells were ﬁxed in formalin for 4 h at room
temperature, and then stained with alcian blue 8GX for 20 min at
room temperature. Stained cells were examined and imaged using
a microscopy (ZEISS, Axio Imager Z1, German).
2.6. RNA extraction, reverse transcription and qPCR
RNA extraction, reverse transcription and qPCR were performed
as described in Supplementary materials. The fold differences in
gene expression were normalized to RNU6, HPRT and GAPDH for
miRNA and mRNA [31–33], and then were calculated using the
DDCt method.
2.7. Protein extraction and Western blot assays
Protein extraction and Western blot were performed as
described in Supplementary materials.2.8. ELISA
The supernatant of cultured cells was collected and kept frozen
until use. The supernatant was centrifuged to remove the
precipitation. The concentration of TNF-alpha protein in the super-
natant was measured by following the manufacturer’s instructions
(Biotechnology, F1163).
2.9. Construction of eukaryotic expression plasmid
Mouse eukaryotic expression GV230 plasmids were purchased
from GeneChem (Supplementary materials, Shanghai, China).
Brieﬂy, the plasmids were constructed following standard DNA
techniques (Supplementary materials). Then, the plasmids were
veriﬁed by sequencing.
2.10. Transfection assays
The transfection assays were performed as described in Supple-
mentary materials.
2.11. Luciferase reporter assay
The potential binding sites of miRNAs were predicted using
online software (miRanda, miRDB, and TargetScan). The primers
for the gene cloning and DNA techniques were in Supplementary
materials.
The cells were seeded into 96-well plates (1.2  104 cells, 100 ll
culture medium per well) and cultured for 24 h. Next, 5 pmol
mmu-miR-193b mimic and 100 ng vector were cotransfected into
each well. At 6 h after transfection, 100 ll culture medium was
added to each well, and cells were cultured for a further 48 h.
The luciferase reporter assay was then performed following the
manufacturer’s instructions (Dual-Glo Luciferase Assay System,
E2940, Promega, USA). Luminescence was measured using a lumi-
nometer (Veritas, 9100-002, USA).
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For each experiment, three completely independent trials were
analyzed (n = 3). Error bars indicate the conﬁdence interval (CI).
Differences were analyzed using the analysis of variance (ANOVA)
among groups or Student’s t-test between groups using SPSS 13.0.
To test the normal distribution of data and the homogeneity of
variances, Gaussian distribution and the homogeneity of variances
were examined with the Shapiro–Wilk test and Levene’s test
before applying the t-test or ANOVA, respectively. All of the data
passed the normal distribution test, but some of the data failed
the test of homogeneity of variances. Multiple comparisons in
ANOVA were performed by using least signiﬁcant differences
(LSD) if the variances were homogenous. Tamhane’s T2 was used
if the variances were not homogenous. For Student’s t test, the t
value was adjusted if the variances were not homogenous. A P val-
ue < 0.05 was regarded as statistically signiﬁcant.
3. Results
3.1. Elevated expression of miR-193b in chondrogenic hADSCs, ATDC5
cells and IL-1b-induced chondrocytes
Cultured hADSCs are thin and spindle-shaped during expansion
(Fig. 1A) [26]. The micromass made from hADSCs in chondrogenic
medium became spherical, dense, hard, and non-transparent on
the 7th day (Fig. 1B). Parafﬁn-embedded sections of the micromass
were stained with alcian blue (Fig. 1C). Expression of miR-193b
and col2a1 increased in chondrogenic hADSCs (Fig. 1D).
We examined the expression of miR-193b in the chondrogenic
ATDC5 cells. Alcian blue staining conﬁrmed the chondrogenic dif-
ferentiation by revealing the matrix nodules (Fig. 2A and B). We
observed an obvious elevation of miR-193b expression and the
expression of chondrocyte-speciﬁc markers in chondrogenic
ATDC5 cells (Fig. 2C).
We also examined the expression of miR-193b in the IL-1b-in-
duced chondrocytes. Signiﬁcantly increased expression of miR-
193b was detected in PMCs, PHCs, and chondrogenic ATDC5 cells
treated with IL-1b (Fig. 3A–C).Fig. 1. Cultured hADSCs, micromasses of chondrogenic hADSCs, and miR-193b expression
100 u/ml penicillin, and 100 mg/ml streptomycin. The hADSCs showed a thin, spindle-lik
hADSCs and maintained in chondrogenic medium for 7 days. Micromasses became sp
extracellular matrix for 7 days (40 ampliﬁcation). (C) After 7 days of chondrogenesis, m
staining (100 ampliﬁcation). (D) RNA was isolated from micromasses after 7 or 14 days
using qPCR.3.2. MiR-193b contributed to the inhibition of early chondrogenic
differentiation
To investigate the effect of miR-193b on chondrogenesis, we
modulated the effects of miR-193b using an miRNA mimic and
an inhibitor. The transfection was highly efﬁcient. The miR-193b
mimic dramatically decreased the expression of early chondro-
genic markers in a dose-dependent manner, including col2a1,
comp, and sox9, and also decreased the levels of TGFB2 and
TGFBR3 (Fig. 4A). Conversely, the miR-193b inhibitor dose-depen-
dently increased the expression of early chondrogenic markers and
of TGFB2 and TGFBR3 (Fig. 4B).
3.3. MiR-193b suppressed TNF-alpha expression in IL-1b treated
mouse primary chondrocytes but had no effect on mmp13 expression
We further examined the role of miR-193b in the IL-1b-induced
inﬂammatory chondrocytes. Surprisingly, we did not ﬁnd a sig-
niﬁcant change in mmp13 expression in ATDC5 cells with either
the miR-193b mimic or the inhibitor. However, we observed sup-
pressed mRNA and protein expression of TNF-alpha with the
miR-193b mimic and elevated expression of TNF-alpha with the
miR-193b inhibitor in mouse chondrocytes (Fig. 5A–C).
3.4. MiR-193b expression was not affected by knockout/overexpression
of sox9/runx2
We further investigated the upstream regulation of miR-193b in
chondrogenic ATDC5 cells. The expression of sox9/runx2 was
manipulated by siRNA and overexpression plasmids. We did not
observe an obvious change in miR-193b expression in ATDC5 cells
with altered sox9/runx2 expression (Supplementary materials).
3.5. TGFB2 and TGFBR3 are target genes of miR-193b in ATDC5 cell
chondrogenesis
TGF-beta2 (TGFB2) and TGFBR3 were predicted to be target
genes of miR-193b (Fig. 6A). To validate TGFB2 as a potential target
gene, we cotransfected cells with mimic or NC (mimic or negative. (A) Third-generation hADSCs were cultured in DMEM plus 10% fetal bovine serum,
e shape at 200 ampliﬁcation. (B) Micromasses were made from 12.5 ll droplets of
herical, hard, dense, and non-transparent after chondrogenesis and secretion of
icromasses were embedded in parafﬁn and cut into sections, followed by alcian blue
of chondrogenesis, and expression levels of miR-193b and col2a1 were determined
Fig. 2. Expression of miR-193b in chondrogenic ATDC5 cells. Mouse ATDC5 cells
were cultured in medium with or without ITS+ Premix for the indicated periods. (A
and B) Cells were ﬁxed and stained with alcian blue to verify chondrogenesis. After
14 days of treatment with ITS+ Premix, ATDC5 cells were highly stained compared
to the negative control group (without ITS+ Premix). (C) Total RNA was extracted
and reverse-transcribed into cDNA. Expression levels of miR-193b and the
chondrogenic markers col2a1, sox9 and comp were measured using qPCR and
calculated using the DDCt method. Expression of mmu-miR-193b was signiﬁcantly
upregulated in ATDC5 cells with ITS+ Premix compared to the negative control
(without ITS+ Premix).
Fig. 3. Expression of miR-193b in PMCs, PHCs and chondrogenic ATDC5 cells with
IL-1b. Cultured PMCs, PHCs and chondrogenic ATDC5 cells (induced with ITS+
Premix for 14 days) were stimulated with 1 ng/ml IL-1b. Total RNA was extracted
and reverse-transcribed into cDNA. The expression of miR-193b was measured
using qPCR and calculated using the DDCt method. (A) Expression of miR-193b was
signiﬁcantly upregulated in PMCs after 4 h of treatment. (B) miR-193b was
upregulated in PHCs after 4 h of treatment. The relative expression level of
mmp13 cannot be calculated because mmp13 could not be detected in PHCs
without IL-1b after 40 cycles. (C) Compared to untreated cells, ATDC5 cells treated
with IL-1b showed upregulation of miR-193b in a time-dependent manner.
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vector containing wild-type or mutated TGFB2/TGFBR3 30-UTR.
Cells cotransfected with the miR-193b mimic and the vector for
the wild-type 30-UTR of either TGFB2 or TGFBR3 showed decreases
of more than 30% in cell luminosity compared to those cotransfect-
ed with mimic NC and wild-type vector (Fig. 6B and C). The muta-
tion of the predicted seed sequence in the 30-UTR of either TGFB2
or TGFBR3 partially restored the luminosity (Fig. 6B and C). Next,
we added recombinant TGFB2 to the culture medium of ATDC5
cells transfected with the miR-193b mimic to restore the activation
of the TGFB2 signaling pathway. Administration of TGFB2 to the
culture medium restored the anti-chondrogenic effect of the
miR-193b mimic in a dose-dependent manner (Fig. 6D).
3.6. MiR-193b repressed the expression of TGFB2 and TGFBR3 and the
phosphorylation of smad3
We further investigated the time-dependent relationships
among the chondrogenic markers col2a1 and col10a1, miR-193b,
and TGFB2 and TGFBR3 in chondrogenic ATDC5 cells (Fig. 7A).Col2a1 peaked at day 14, decreased at day 21, and remained low
until day 28. Col10a1 peaked at day 28. miR-193b was elevated
at day 14 and continued to increase until day 28. In response to
the elevation of miR-193b, TGFBR3 decreased at day 28, and TGFB2
decreased at day 21 but then increased slightly at day 28. We spec-
ulate that there may be other factors regulating TGFB2 and TGFBR3
transcription during chondrogenesis.
We investigated the protein expression of TGFB2 and TGFBR3
and the phosphorylation of smad3 in chondrogenic ATDC5 cells
with modulated miR-193b. We found that miR-193b repressed
TGFB2 and TGFBR3 expression and smad3 phosphorylation
(Fig. 7B). These results show that miR-193b may negatively regu-
late the TGF-beta signaling pathway by repressing the protein
expression of TGFB2 and TGFBR3.
Fig. 4. Inhibitory effect of miR-193b on early chondrogenesis of ATDC5 cells. The
mimic or inhibitor was transfected into ATDC5 cells with Lipofectamine 2000 for
6 h. Next, ATDC5 cells were cultured in chondrogenic medium containing ITS+
Premix for 4 days. (A) The mimic of miR-193b inhibited the mRNA expression of the
chondrogenic markers col2a, comp and sox9, as well as the expression of TGFB2 and
TGFBR3. (B) The inhibitor of miR-193 enhanced the mRNA expression of these
markers and of TGFB2 and TGFBR3.
Fig. 5. MiR-193b inhibited TNF-alpha expression in PMCs but did not affect mmp13
expression. PMCs were transfected with the miR-193b mimic or inhibitor and
treated with 1 ng/ml IL-1b for 4 h. TNF-alpha and mmp13 mRNA levels were
measured by qPCR. Additionally, the TNF-alpha protein concentration in the
supernatant was detected by ELISA. (A) miR-193b mimic inhibited the expression of
TNF-alpha mRNA but did not alter mmp13 mRNA. (B) miR-193b inhibitor enhanced
the expression of TNF-alpha mRNA but did not alter mmp13 mRNA. (C) miR-193b
mimic reduced the expression of TNF-alpha protein in the supernatant. TNF-alpha
protein concentrations were undetectable in PMC culture mediumwith 50 nMmiR-
193b mimic.
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According to previous studies, chondrogenic and hypertrophic
phenotypes were identiﬁed at approximately 14 and 28 days in
culture, respectively, in ATDC5 cells grown in chondrogenic culture
medium [34]. In this study, we found miR-193b negatively regulat-
ed the early chondrogenic markers sox9, comp and col2a1, sug-
gesting a negative role for miR-193b in early chondrogenesis.
Hypertrophic and early chondrogenic differentiation mutually
repress each other, as suggested by previous studies [5–8,40,41].
We speculate that miR-193b may mediate the repression of hyper-
trophic differentiation on early chondrogenesis.
TGF-beta is a cytokine that is secreted into the microenviron-
ments around chondrogenic ATDC5 cells and can bind to the
TGF-beta receptor in an autocrine manner to regulate downstream
gene expression, including activating genes of the early chondro-
genic phenotype [35]. TGFB2 has been found to positively regulate
mesenchymal condensation, the early phase of chondrogenesis
[35]. Phosphorylated smad3 has been shown to mediate the effect
of TGF-beta on early chondrogenesis [13], and TGFBR3 acts as a
coreceptor to bind and present TGF-beta ligand to the heteromeric
protein kinase receptors of the TGF-beta receptor complex. There-
fore, TGFBR3 can enhance the binding of TGF-beta to the receptor
complex, thereby strengthening the TGF-beta signaling pathway
[15]. In the current study, miR-193b was shown to potentially bind
to the speciﬁc seed sequence of the 30-UTRs of TGFB2 and TGFBR3,
inhibit the expression of TGFB2 and TGFBR3, and repress the phos-
phorylation of smad3 and early chondrogenesis. Zhong Q has
shown that the TGF-beta signaling pathway was regulated by
miR-193b via the direct binding of miR-193b to smad3 mRNA
[36]. These data and Zhong Q’s study suggest that miR-193b mayinhibit early chondrogenesis in ATDC5 cells via the inactivation
of the TGF-beta signaling pathway, possibly by targeting the auto-
crine activation of TGFB2 and TGFBR3 in the cell membrane and of
intracellular smad3.
We observed that exogenous TGFB2 could prevent the inhibi-
tion of sox9 by miR-193b during chondrogenesis. Sox9 is consid-
ered a pivotal transcriptional factor in chondrogenesis [9]. These
results further suggest that miR-193b can repress chondrogenesis
by inhibiting the TGF-beta pathway. However, because the TGFB2
signaling pathway was shown to positively regulate chondrogene-
sis [37–39], this apparent de-repressive effect could also be
achieved by the positive effect of exogenous TGFB2 on ATDC5 cell
chondrogenesis, which counteracted the repression of chondro-
genesis by miR-193b.
Previously, miR-193b has been shown to inhibit tumor cell pro-
liferation [42–46]. One of these studies found approximately 30%
Fig. 6. MiR-193b inhibited early chondrogenesis in ATDC5 cells by targeting TGFB2
and TGFBR3. (A) TGFB2 and TGFBR3 were predicted potential target genes of miR-
193b. (B and C) Cells seeded into 96-well plates were cotransfected with 100 ng
pmiR-RB-TGFB2/TGFBR3-30-UTRwildtype/mutation (pmiR-RB-TGFB2-30-UTRwildtype: Tgf-
b2-WT; pmiR-RB-TGFB2-30-UTRmutation: Tgfb2-Mut; pmiR-RB-TGFBR3-30-UTRwild-
type: Tgfbr3-WT; pmiR-RB-TGFBR3-30-UTRmutation: Tgfbr3-Mut) and 5 pmol miR-
193b mimic or NC (miR-193b mimic: mmu-miR-193b; negative control for miR
mimic: NC) per well and were cultured for 24 h. Next, the luminescence was
measured. (B) The luminescence decreased by more than 30% in cells cotransfected
with Tgfb2-WT and mmu-miR-193b compared to cells cotransfected with Tgfb2-
WT and NC. The luminescence was signiﬁcantly restored in cells cotransfected with
Tgfb2-Mut and mmu-miR-193b compared to cells cotransfected with Tgfb2-WT
and mmu-miR-193b. (C) The luminescence decreased by more than 30% in cells
cotransfected with Tgfbr3-WT and mmu-miR-193b compared to cells cotransfected
with Tgfbr3-WT and NC. Luminescence was signiﬁcantly restored in cells cotrans-
fected with Tgfbr3-Mut and mmu-miR-193b compared to cells cotransfected with
Tgfbr3-WT and mmu-miR-193b. (D) ATDC5 cells were transfected with 50 nMmiR-
193b mimic, followed by 4 days in chondrogenesis induction medium (with ITS+
Premix) and various concentrations of recombinant TGFB2. The expression of sox9
was measured using qPCR. The miR-193b mimic inhibited the expression of sox9,
but exogenous TGFB2 restored the inhibitory effect of the miR-193b mimic on sox9
expression in a dose-dependent manner. These results indicate that miR-193b may
inhibit ATDC5 cell chondrogenesis by targeting TGFB2 and TGFBR3.
Fig. 7. The expression of TGFB2 and TGFBR3 and the phosphorylation of smad3
were repressed by miR-193b. (A) Total RNA was isolated from chondrogenic ATDC5
cells at the indicated time point and reverse-transcribed. mRNA expression levels of
miR-193b, col2a1, col10a1, TGFB2 and TGFBR3 were measured using qPCR. Col2a1
peaked at day 14, and col10a1 peaked at day 28, indicating early chondrogenic
differentiation and hypertrophic differentiation at days 14 and 28, respectively.
TGFB2 and TGFBR3 were downregulated when miR-193b was upregulated,
although they were not strictly ‘‘mirror opposites’’. (B) Repression by miR-193b
of the protein expression of TGFB2 and TGFBR and the phosphorylation of smad3.
Four days after transfection, protein was extracted. Western blots were used to
assess the protein expression levels of TGFB2, TGFBR3, smad3 and tubulin and the
phosphorylation of smad3. MiR-193b markedly downregulated the protein expres-
sion of TGFB2 and TGFBR3 and the phosphorylation of smad3. Total smad3 was
slightly downregulated by miR-193b, consistent with the previous literature [36].
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ﬁreﬂy luciferase vector with the cyclin D1 30-UTR, and that work
successfully identiﬁed cyclin D1 as a target gene of miR-193b
[44]. However, most previous studies of miR-193b did not identify
the target genes and possible mechanisms. In the present study,
TGFB2 and TGFBR3 were identiﬁed as possible target genes of
miR-193b. The TGF-beta signaling pathway has previously been
shown to enhance tumor cell proliferation [47,48]. We suspect that
miR-193b may suppress tumor cell proliferation, at least partly by
targeting TGFB2 and TGFBR3.
IL-1b has been broadly used to stimulate chondrocytes in stud-
ies of arthritis [49,50]. And destruction of the cartilage matrix
begins when chondrocytes are stimulated by a local network of
inﬂammatory cytokines, including the proinﬂammatory cytokines
TNF-alpha and IL-1b [51]. Anti-inﬂammatory medicines targeting
IL-1b and TNF-alpha have been considered innovative osteoarthri-
tis therapies [52]. In the present study, we found that miR-193b
could be time-dependently upregulated in cells stimulated with
IL-1b and could inhibit TNF-alpha expression. Based on these
results, miR-193b may participate in the negative regulation of
the local inﬂammatory web and contribute to limiting the strength
of inﬂammation. Wang HJ found that miR-193b expression was
negatively correlated to inﬂammation and sepsis [53]. Arner E
found that miR-193b inhibited expression of the proinﬂammatory
cytokines CCL2 and IL-6 through targeting ETS1 and MAX [54].
Because ETS1 may bind to the promoter of TNF-alpha and initiate
transcription [55], we speculate that ETS1 may mediates the
repression of TNF-alpha by miR-193b in inﬂamed chondrocytes.
CCL2 is an important chemokine in symptomatic osteoarthritis
[56,57], and TNF-alpha has been shown to induce CCL2 expression
in the synovial tissue of rheumatism [58,59]. Based on these rela-
1046 C. Hou et al. / FEBS Letters 589 (2015) 1040–1047tionships among miR-193b, CCL2, TNF-alpha and mmp13, miR-
193b may indirectly protect cartilage by regulating the strength
of inﬂammation.
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